Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals.

2022

Purpose: To assess whether HCC (LR-5) occurrence may be associated with the presence of Liver Imaging Reporting and Data System (LI-RADS) indeterminate observations in patients with hepatitis C virus infection treated with direct acting antiviral (DAA) therapy. Materials and methods: This retrospective study included patients with HCV-related cirrhosis who achieved sustained virologic response (SVR) after DAA therapy between 2015 and 2019 and submitted to CT/MRI follow-ups with a minimum interval time of six months before and after DAA. Two blinded readers reviewed CT/MRI to categorize observations according to LI-RADS version 2018. Differences in rate of LI-RADS 5 observations (i.e., LR-5)…

liver cirrhosiClinical Biochemistrychronic hepatitis Cmagnetic resonance imaginghepatocellular carcinoma; sustained virologic response; chronic hepatitis C; liver cirrhosis; magnetic resonance imaginghepatocellular carcinomasustained virologic response.Diagnostics (Basel, Switzerland)
researchProduct

Focal confluent fibrosis in cirrhotic liver: natural history studied with serial CT.

2009

OBJECTIVE: The objective of this study was to assess the long-term natural history of focal confluent fibrosis in cirrhotic liver with CT. MATERIALS AND METHODS: Two radiologists retrospectively reviewed in consensus 118 liver CT examinations in 26 patients (19 men, seven women; age range, 32-68 years; mean age, 50 years) performed over approximately 6 years. Helical CT scans were obtained before and 30-35 and 65-70 seconds after injection of 125-150 mL of contrast medium at a rate of 4-5 mL/s. Proof of cirrhosis was based on liver transplantation (n = 6), biopsy (n = 9), or imaging findings (n = 11). The number, location, and attenuation of fibrotic lesions and presence of trapped vessels …

liver cirrhosis CTSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD

2021

Background and aim: Coffee intake exerts protective effects against non-alcoholic fatty liver disease (NAFLD), although without fully cleared mechanisms. In this study we aimed to assess whether coffee consumption may influence the expression of long non-coding RNAs (lncRNAs) in the liver. Methods: C57BL/6J mice were fed a 12-week standard diet (SD), high-fat diet (HFD) or HFD plus decaffeinated coffee solution (HFD + coffee). Expression of specific lncRNAs involved in NAFLD was analyzed by real-time PCR. For the most differentially expressed lncRNAs, the analysis was also extended to their mRNA targets. Results: Decaffeinated coffee intake reduced body weight gain, prevented NAFLD, lowered…

lncRNA.Liver CirrhosisMalemedicine.medical_specialtyGm16551; H19; NAFLD; coffee; lncRNA; Animals; Coffee; Disease Models Animal; Fatty Liver; Gene Expression; Liver; Liver Cirrhosis; Male; Mice; Mice Inbred C57BL; Non-alcoholic Fatty Liver Disease; RNA Long NoncodingCoenzyme ACircadian clockcoffeeGene ExpressionBiologyInbred C57BLArticlechemistry.chemical_compoundMicelncRNADownregulation and upregulationFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineAnimalsTX341-641Messenger RNANutrition and DieteticsH19Nutrition. Foods and food supplyAnimalGm16551Fatty liverNAFLD; coffee; lncRNA; Gm16551; H19nutritional and metabolic diseasesmedicine.diseaseMice Inbred C57BLFatty LiverDisease Models AnimalEndocrinologychemistryLiverLipogenesisDisease ModelsRNARNA Long NoncodingLong NoncodingSteatosisFood Science
researchProduct

Lymphocytes from hepatic inflammatory infiltrate kill rat hepatocytes in primary culture

1990

In the last few years it has become possible in the liver to isolate lymphocytes from inflammatory infiltrates and to culture them in vitro. Most of the lymphocyte clones obtained are CD 8 + cytotoxic cells, but interactions between these lymphocytes and hepatocytes in primary culture have not been analysed previously. In this study, cloned human T lymphocytes from liver biopsies and from the peripheral blood of patients with chronic hepatitis B or primary biliary cirrhosis, after phenotypical and functional characterization into CD 8+ or CD 4+ cytotoxic lymphocytes, were activated in an antigen-independent fashion by adding either anti CD 3 or anti CD 2/R-3 monoclonal antibodies to the cel…

medicine.drug_classBiopsyLymphocyteBiologyMonoclonal antibodyPrimary biliary cirrhosismedicineAnimalsHumansCytotoxic T cellCytotoxicityCells CulturedHepatitis ChronicL-Lactate DehydrogenaseLiver Cirrhosis BiliaryGeneral MedicineHepatitis Bmedicine.diseaseMolecular biologyIn vitroClone CellsRatsMicroscopy Electronmedicine.anatomical_structureLiverCell cultureHepatocyteImmunologyT-Lymphocytes CytotoxicVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

2021

ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk fac…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineantiviral therapymedicineHumansPropensity Scoreantiviral therapy; hepatocellular carcinoma; meta-analysisbusiness.industryLiver NeoplasmsGastroenterologyAntiviral therapyPatient datahepatocellular carcinomamedicine.disease3. Good healthmeta-analysis030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinomaRelative riskCohort030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeoplasm Recurrence LocalbusinessDirect acting
researchProduct

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Primary Biliary Cholangitis: advances in management and treatment of the disease

2017

Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10Â year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, b…

medicine.medical_specialtyCholagogues and CholereticsCirrhosisPrimary Biliary CholangitisCholangitisDiseaseChenodeoxycholic AcidGastroenterologyEnd Stage Liver Disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePrimary biliary cirrhosisDuctopeniaAlkaline phosphatase; Budesonide; Fibrates; Obeticholic acid; Ursodeoxycholic acid; Hepatology; GastroenterologyMED/12 - GASTROENTEROLOGIAInternal medicineAlkaline phosphatasemedicineHumansFibrateSettore SECS-P/01 - Economia PoliticaBudesonideCholestasisHepatologyAlkaline phosphatase; Budesonide; Fibrates; Obeticholic acid; Ursodeoxycholic acidbusiness.industryGastroenterologyObeticholic acidHepatologymedicine.diseaseUrsodeoxycholic acidchemistryUrsodeoxycholic acid030220 oncology & carcinogenesisObeticholic acidDisease Progression030211 gastroenterology & hepatologyDrug Therapy CombinationbusinessFibratesbiologicalRare diseasemedicine.drug
researchProduct

Autoimmune hepatitis and overlap syndromes

2002

Autoimmune hepatitis (AIH) is an immune-mediated, autodestructive liver disease with hepatocytes as target cells, mostly affecting young women. Primary biliary cirrhosis (PBC) is also regarded as an autoimmune liver disease with bile duct epithelia as the target cells, resulting in a continuous loss of bile ducts. Both diseases may occur simultaneously in their full manifestations in about 10% to 20% of cases, thus constituting an overlap syndrome with PBC directing the course of the disease. AIH may also occur simultaneously with primary sclerosing cholangitis (PSC), with a frequency of between 2% and 8% of patients with PSC. In most cases, AIH precedes manifestation of PSC. In children, t…

medicine.medical_specialtyCholangitis SclerosingAutoimmune hepatitisDiseasedigestive systemGastroenterologyPrimary sclerosing cholangitisLiver diseasePrimary biliary cirrhosisimmune system diseasesInternal medicinemedicineHumansAutoimmune liver diseaseAutoantibodiesHepatologyLiver Cirrhosis BiliaryBile ductbusiness.industryOverlap syndromemedicine.diseasedigestive system diseasesHepatitis Autoimmunemedicine.anatomical_structureLiverbusinessClinics in Liver Disease
researchProduct

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

2020

Background & Aims The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. Methods We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD …

medicine.medical_specialtyCirrhosisCarcinoma HepatocellularMedizinPilot ProjectsMilan criteriaGastroenterologySensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineBiomarkers TumorHumansProtein PrecursorsneoplasmsHepatologyReceiver operating characteristicbusiness.industryLiver NeoplasmsGastroenterologyArea under the curvemedicine.diseasedigestive system diseasesROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaCase-Control StudiesCohort030211 gastroenterology & hepatologyProthrombinalpha-FetoproteinsbusinessLiver cancerBiomarkersCohort study
researchProduct

A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.

2020

The rising prevalence of the metabolic syndrome has led to an increase of non-alcoholic fatty liver disease (NAFLD), and its progressive-inflammatory form called non-alcoholic steatohepatitis (NASH). In recent years, NAFLD and NASH have become major risk factors for developing liver cirrhosis and hepatocellular carcinoma (HCC). In this case, we report a 46-year-old patient with type 2 diabetes mellitus and metabolic comorbidities including obesity and arterial hypertension, who was referred because of rising liver enzymes. After clinical and diagnostic evaluation, the patient was diagnosed with NASH-associated liver cirrhosis, Child-Pugh stage B. A normal blood sugar level was difficult to …

medicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityLiver transplantationChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineFatal OutcomeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicineObesityMetabolic Syndromebusiness.industryFatty liverLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesDiabetes Mellitus Type 2Hepatocellular carcinomaHypertension030211 gastroenterology & hepatologyMetabolic syndromeSteatohepatitisInsulin ResistancebusinessZeitschrift fur Gastroenterologie
researchProduct